PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Signs and symptoms • Causes of cancer pain • Assessment of cancer pain • Treatment • Epidemiology PART 06: Pipeline portfolio • Information on pipeline candidates PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by drug class • Opioids • Non-steroidal anti-inflammatory drugs • Others PART 09: Geographical segmentation • Cancer pain therapeutics market in Americas • Cancer pain therapeutics market in EMEA • Cancer pain therapeutics market in APAC PART 10: Market drivers PART 11: Impact of drivers PART 12: Market challenges PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape • Competitive scenario • Market analysis 2014 PART 16: Vendor landscape • Other prominent vendors PART 17: Key vendor analysis • BioDelivery Sciences • ProStrakan • Teva Pharmaceuticals PART 18: Appendix • List of abbreviations PART 19: Explore Technavio LOE Exhibit 01: Product offerings Exhibit 02: Classification of cancer pain Exhibit 03: Acute pain syndromes Exhibit 04: Chronic pain syndromes Exhibit 05: Causes of pain from cancer Exhibit 06: Causes of pain from procedures and surgery Exhibit 07: Causes of pain from other cancer treatments Exhibit 08: Common causes of pain in cancer patients Exhibit 09: Cancer pain assessment Exhibit 10: Types of pain scales Exhibit 11: Treatment options for cancer pain Exhibit 12: Commonly used non-opioids for pain management Exhibit 13: Commonly used adjuvant medicines for cancer pain Exhibit 14: Management of cancer pain Exhibit 15: Pipeline molecules for cancer pain therapeutics market Exhibit 16: Global cancer pain therapeutics market ($ millions) Exhibit 17: Five forces analysis Exhibit 18: Global cancer pain therapeutics market by drug class Exhibit 19: Global cancer pain therapeutics market by geographical segmentation 2014 Exhibit 20: Cancer pain therapeutics market in different regions, 2014-2019 ($ millions) Exhibit 21: Cancer pain therapeutics market in the Americas 2014-2019 ($ millions) Exhibit 22: Cancer pain therapeutics market in EMEA 2014-2019 ($ millions) Exhibit 23: Cancer pain therapeutics market in APAC 2014-2019 ($ millions) Exhibit 24: Impact of drivers Exhibit 25: Impact of drivers and challenges Exhibit 26: BioDelivery Sciences: Key takeaways Exhibit 27: ProStrakan: Key takeaways Exhibit 28: Teva Pharmaceuticals: Key takeaways Exhibit 29: BioDelivery Sciences: Product pipeline Exhibit 30: Teva Pharmaceuticals: Business segmentation by revenue 2014 Exhibit 31: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions) Exhibit 32: Teva Pharmaceuticals: Geographical segmentation by revenue 2014

BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals, Daiichi Sankyo, Eli-lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, WEX Pharmaceuticals.